United States

People: Pieris Pharmaceuticals Inc (PIRS.OQ)

PIRS.OQ on NASDAQ Stock Exchange Capital Market

23 Aug 2019
Change (% chg)

$-0.14 (-3.08%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Yoder, Stephen 

Mr. Stephen S. Yoder is President, Chief Executive Officer, Director of the Company. He has been appointed to the Company on the closing of the Acquisition of Pieris, Pieris Operating, on December 17, 2014. Pieris, is a former stockholders of Pieris Operating. Prior to joining Pieris Operating, from July 2003 to December 2010 he led the intellectual property and legal departments at MorphoSys AG, a biotechnology company involved in the development and research of antibodies, as General Counsel. Prior to MorphoSys AG, from September 1999 to June 2003 he worked in several Washington, D.C. law firms, specializing in a life sciences intellectual property practice. Mr. Yoder holds degrees in molecular biology and Spanish from Grove City College and a Juris Doctorate, with honors, from The George Washington University Law School. As an attorney, he is licensed to practice before the United States Patent and Trademark Office, and in the jurisdictions of Maryland and Washington, D.C. We believe that Mr. Yoder adds value to our Board of Directors based on his intimate knowledge of our business plans and strategies of our business and his years of experience in the biotechnology and life sciences industry.

Basic Compensation

Total Annual Compensation, USD 320,677
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,658,980
Fiscal Year Total, USD 1,979,660

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --